全文获取类型
收费全文 | 1172篇 |
免费 | 49篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 41篇 |
妇产科学 | 4篇 |
基础医学 | 87篇 |
口腔科学 | 11篇 |
临床医学 | 66篇 |
内科学 | 304篇 |
皮肤病学 | 27篇 |
神经病学 | 112篇 |
特种医学 | 316篇 |
外科学 | 85篇 |
综合类 | 14篇 |
预防医学 | 32篇 |
眼科学 | 4篇 |
药学 | 94篇 |
中国医学 | 2篇 |
肿瘤学 | 43篇 |
出版年
2023年 | 6篇 |
2022年 | 6篇 |
2021年 | 28篇 |
2020年 | 10篇 |
2019年 | 10篇 |
2018年 | 23篇 |
2017年 | 6篇 |
2016年 | 11篇 |
2015年 | 18篇 |
2014年 | 30篇 |
2013年 | 33篇 |
2012年 | 37篇 |
2011年 | 36篇 |
2010年 | 33篇 |
2009年 | 32篇 |
2008年 | 27篇 |
2007年 | 50篇 |
2006年 | 27篇 |
2005年 | 31篇 |
2004年 | 28篇 |
2003年 | 24篇 |
2002年 | 23篇 |
2001年 | 22篇 |
2000年 | 20篇 |
1999年 | 19篇 |
1998年 | 48篇 |
1997年 | 40篇 |
1996年 | 62篇 |
1995年 | 46篇 |
1994年 | 35篇 |
1993年 | 38篇 |
1992年 | 11篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 31篇 |
1988年 | 36篇 |
1987年 | 29篇 |
1986年 | 29篇 |
1985年 | 40篇 |
1984年 | 21篇 |
1983年 | 22篇 |
1982年 | 27篇 |
1981年 | 24篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 7篇 |
1977年 | 26篇 |
1976年 | 18篇 |
1975年 | 14篇 |
1973年 | 2篇 |
排序方式: 共有1245条查询结果,搜索用时 15 毫秒
1.
2.
Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
下载免费PDF全文
![点击此处可从《British journal of pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
L. Negri G. Improta R. Lattanzi R. L. Potenza F. Luchetti P. Melchiorri 《British journal of pharmacology》1995,116(7):2931-2938
1. In rats, the interaction between the mu-opioid agonist dermorphin and the delta-opioid agonist [D-Ala2, Glu4]deltorphin was studied in binding experiments to delta-opioid receptors and in the antinociceptive test to radiant heat. 2. When injected i.c.v., doses of [D-Ala2, Glu4]deltorphin higher than 20 nmol produced antinociception in the rat tail-flick test to radiant heat. Lower doses were inactive. None of the doses tested elicited the maximum achievable response. This partial antinociception was accomplished with an in vivo occupancy of more than 97% of brain delta-opioid receptors and of 17% of mu-opioid receptors. Naloxone (0.1 mg kg-1, s.c.), and naloxonazine (10 mg kg-1, i.v., 24 h before), but not the selective delta-opioid antagonist naltrindole, antagonized the antinociception. 3. In vitro competitive inhibition studies in rat brain membranes showed that [D-Ala2, Glu4]deltorphin displaced [3H]-naltrindole from two delta-binding sites of high and low affinity. The addition of 100 microM Gpp[NH]p produced a three fold increase in the [D-Ala2, Glu4]deltorphin Ki value for both binding sites. The addition of 10 nM dermorphin increased the Ki value of the delta-agonist for the high affinity site five times. When Gpp[NH]p was added to the incubation medium together with 10 nM dermorphin, the high affinity Ki of the delta-agonist increased 15 times. 4. Co-administration into the rat brain ventricles of subanalgesic doses of dermorphin and [D-Ala2, Glu4]deltorphin resulted in synergistic antinociceptive responses. 5. Pretreatment with naloxone or with the non-equilibrium mu-antagonists naloxonazine and beta-funaltrexamine completely abolished the antinociceptive response of the mu-delta agonist combinations. 6. Pretreatment with the delta-opioid antagonists naltrindole and DALCE reduced the antinociceptive response of the dermorphin-[D-Ala2, Glu4]deltorphin combinations to a value near that observed after the mu-agonist alone. At the dosage used, naltrindole occupied more than 98% of brain delta-opioid receptors without affecting mu-opioid-receptors. 7. These data suggest that in the rat tail-flick test to radiant heat, mu- and delta-opioid agonists co-operate positively in evoking an antinociceptive response. Although interactions between different opioid pathways cannot be excluded, in vitro binding results indicate that this co-operative antinociception is probably mediated by co-activation of the delta-opioid receptors at the cellular level by the mu- and delta-agonist. 相似文献
3.
4.
Claudio R Cernea Alberto R Ferraz Inês V de Castro Miriam N Sotto Angela F Logullo Carlos E Bacchi André S Potenza 《Otolaryngology--head and neck surgery》2006,134(3):471-475
BACKGROUND: Some skin carcinomas may be very aggressive. Increased expression of the protein p53 has been associated with tumor aggressiveness. In this study, p53 expression was evaluated in basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) with skull base invasion, and was compared to tumors with good outcome. STUDY DESIGN AND SETTING: Expression of p53 was immunohistochemically analyzed and it was reported as present or absent in 24 BCC and 11 SCC with skull base invasion. Control group (good outcome) included 23 BCC and 10 SCC. RESULTS: Expression of p53 was noted in 70.83% of BCC with skull base invasion, compared to 43.48% in the control group (P = 0.058). Regarding SCC, p53 positivity was noted in only 9.09% of SCC with skull base invasion, compared to 40.00% in the control group (P = 0.149). CONCLUSIONS: In this study, p53 expression was more common among BCC with skull base invasion, compared to controls with good outcome, and the difference was considered marginally significant. This proportion was reversed in SCC, but the difference was not statistically significant. EBM rating: B-3b. 相似文献
5.
6.
7.
A randomized controlled trial of electromagnetic therapy in the primary care management of venous leg ulceration 总被引:1,自引:1,他引:0
OBJECTIVE: The aim was to establish the potential efficacy, tolerabilityand side-effect profile of electromagnetic therapy as an adjunctto conventional dressings in the treatment of venous leg ulcers. METHOD: A prospective, randomized, double blind controlled clinicaltrial was carried out in a dedicated leg ulcer clinic basedin one urban general practice. Nineteen patients with leg ulcersof confirmed venous aetiology were assessed. The main outcomemeasures were rate and scale of venous leg ulcer healing, changesin patient-reported pain levels, quality of life, degree ofmobility, side effect profile and acceptability to patientsand staff. RESULTS: Sixty-eight per cent of patients attending this dedicated clinicachieved improvements in the size of their ulcer (4, 21%, healedfully) and in reduced pain levels (P < 0.05) during the trial,despite the chronicity of ulcer histories. Patients treatedwith electromagnetic therapy at 800 Hz were found at day 50to have significantly greater healing (P < 0.05) and paincontrol (P < 0.05) than placebo therapy or treatment with600 Hz. All patients reported improved mobility at the end ofthe study. The electromagnetic therapy was well tolerated bypatients, with no differences between groups in reporting adverseevents, and proved acceptable to staff. CONCLUSION: Despite the small numbers in this pilot study, electromagnetictherapy provided significant gains in the healing of venousleg ulcers and reduction in pain. Keywords. Electromagnetic therapy, RCT, leg ulcers, primary care. 相似文献
8.
9.
10.